# PFE catalysts: PFIZER INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/pfe/catalysts

> PFIZER INC (PFE) has 185 upcoming catalysts. The next is the Nurtec Odt (rimegepant sulfate) primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | PFIZER INC |
| Ticker | PFE (NYSE) |
| SEC CIK | 78003 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/pfe |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 23, 2016 | [Xeljanz (tofacitinib citrate) FDA approval](https://sec-api.dev/pdufa/tofacitinib) | PFE |  | completed, approved | "NDA208246 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20160223, review_priority STANDARD; sponsor_name PFIZER; product XELJANZ XR (TOFACITINIB CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208246%22)) |
| August 19, 2016 | [Troxyca Er (naltrexone hydrochloride; oxycodone hydrochloride) FDA approval](https://sec-api.dev/pdufa/naltrexone-oxycodone) | PFE |  | completed, approved | "NDA207621 ORIG-1 (Type 3 - New Dosage Form and Type 4 - New Combination): submission_status AP, submission_status_date 20160819, review_priority STANDARD; sponsor_name PFIZER; product TROXYCA ER (NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207621%22)) |
| August 17, 2017 | [Besponsa (inotuzumab ozogamicin) FDA approval](https://sec-api.dev/pdufa/inotuzumab-ozogamicin) | PFE |  | completed, approved | "BLA761040 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170817, review_priority PRIORITY; sponsor_name WYETH PHARMS INC; product BESPONSA (INOTUZUMAB OZOGAMICIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761040%22)) |
| September 1, 2017 | [Mylotarg (gemtuzumab ozogamicin) FDA approval](https://sec-api.dev/pdufa/gemtuzumab-ozogamicin) | PFE |  | completed, approved | "BLA761060 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20170901, review_priority STANDARD; sponsor_name WYETH PHARMS INC; product MYLOTARG (GEMTUZUMAB OZOGAMICIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761060%22)) |
| November 3, 2017 | [VELCADE® (bortezomib) complete response letter (CRL)](https://sec-api.dev/pdufa/bortezomib) | PFE |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22209191_2018_Orig1s000OtherActionLtrs.pdf%22)) |
| December 13, 2017 | [Ixifi (infliximab-qbtx) FDA approval](https://sec-api.dev/pdufa/infliximab-qbtx) | PFE |  | completed, approved | "BLA761072 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20171213, review_priority STANDARD; sponsor_name PFIZER INC; product IXIFI (INFLIXIMAB-QBTX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761072%22)) |
| February 22, 2018 | [VELCADE® (bortezomib) complete response letter (CRL)](https://sec-api.dev/pdufa/bortezomib) | PFE |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22209191_2018_Orig1s000OtherActionLtrs.pdf%22)) |
| March 19, 2018 | [Daptomycin (daptomycin) complete response letter (CRL)](https://sec-api.dev/pdufa/daptomycin) | PFE |  | completed, complete response letter | "We have completed our review of this application, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22210282_2022_Orig1s000OtherActionLtrs.pdf%22)) |
| April 20, 2018 | [Trazimera (trastuzumab-qyyp) complete response letter (CRL)](https://sec-api.dev/pdufa/trastuzumab-qyyp) | PFE |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761081_2019_Orig1s000OtherActionLtrs.pdf%22)) |
| May 15, 2018 | [Retacrit (epoetin alfa-epbx) FDA approval](https://sec-api.dev/pdufa/epoetin-alfa-epbx) | PFE |  | completed, approved | "BLA125545 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20180515, review_priority STANDARD; sponsor_name HOSPIRA INC; product RETACRIT (EPOETIN ALFA-EPBX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125545%22)) |
| July 20, 2018 | [Nivestym (filgrastim-aafi) FDA approval](https://sec-api.dev/pdufa/filgrastim-aafi) | PFE |  | completed, approved | "BLA761080 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20180720, review_priority STANDARD; sponsor_name HOSPIRA INC; product NIVESTYM (FILGRASTIM-AAFI)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761080%22)) |
| July 24, 2018 | [Doxercalciferol (doxercalciferol) FDA approval](https://sec-api.dev/pdufa/doxercalciferol) | PFE |  | completed, approved | "NDA208614 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20180724, review_priority STANDARD; sponsor_name HOSPIRA; product DOXERCALCIFEROL (DOXERCALCIFEROL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208614%22)) |
| September 27, 2018 | [Vizimpro (dacomitinib) FDA approval](https://sec-api.dev/pdufa/dacomitinib) | PFE |  | completed, approved | "NDA211288 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180927, review_priority PRIORITY; sponsor_name PFIZER; product VIZIMPRO (DACOMITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211288%22)) |
| October 16, 2018 | [Talzenna (talazoparib tosylate) FDA approval](https://sec-api.dev/pdufa/talazoparib) | PFE |  | completed, approved | "NDA211651 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20181016, review_priority PRIORITY; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211651%22)) |
| November 2, 2018 | [Lorbrena (lorlatinib) FDA approval](https://sec-api.dev/pdufa/lorlatinib) | PFE |  | completed, approved | "NDA210868 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20181102, review_priority PRIORITY; sponsor_name PFIZER; product LORBRENA (LORLATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210868%22)) |
| November 21, 2018 | [Daurismo (glasdegib maleate) FDA approval](https://sec-api.dev/pdufa/glasdegib) | PFE |  | completed, approved | "NDA210656 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20181121, review_priority PRIORITY; sponsor_name PFIZER; product DAURISMO (GLASDEGIB MALEATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210656%22)) |
| March 11, 2019 | [Trazimera (trastuzumab-qyyp) FDA approval](https://sec-api.dev/pdufa/trastuzumab-qyyp) | PFE |  | completed, approved | "BLA761081 ORIG-1: submission_status AP, submission_status_date 20190311, review_priority STANDARD; sponsor_name PFIZER INC; product TRAZIMERA (TRASTUZUMAB-QYYP)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761081%22)) |
| June 27, 2019 | [Zirabev (bevacizumab-bvzr) FDA approval](https://sec-api.dev/pdufa/bevacizumab-bvzr) | PFE |  | completed, approved | "BLA761099 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20190627, review_priority STANDARD; sponsor_name PFIZER INC; product ZIRABEV (BEVACIZUMAB-BVZR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761099%22)) |
| July 23, 2019 | [Ruxience (rituximab-pvvr) FDA approval](https://sec-api.dev/pdufa/rituximab-pvvr) | PFE |  | completed, approved | "BLA761103 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20190723, review_priority STANDARD; sponsor_name PFIZER INC; product RUXIENCE (RITUXIMAB-PVVR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761103%22)) |
| November 1, 2019 | [IBRANCE® (palbociclib) FDA approval](https://sec-api.dev/pdufa/palbociclib) | PFE |  | completed, approved | "NDA212436 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20191101, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22)) |
| November 5, 2019 | [Epinephrine Bitartrate In 0.9% Sodium Chloride (epinephrine bitartrate) FDA approval](https://sec-api.dev/pdufa/epinephrine) | PFE |  | completed, approved | "NDA209359 ORIG-1 (Type 7 - Drug Already Marketed without Approved NDA): submission_status AP, submission_status_date 20191105, review_priority STANDARD; sponsor_name HOSPIRA; product EPINEPHRINE (EPINEPHRINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209359%22)) |
| November 15, 2019 | [Abrilada (adalimumab-afzb) FDA approval](https://sec-api.dev/pdufa/adalimumab-afzb) | PFE |  | completed, approved | "BLA761118 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20191115, review_priority STANDARD; sponsor_name PFIZER INC; product ABRILADA (ADALIMUMAB-AFZB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761118%22)) |
| January 16, 2020 | [Ixifi (infliximab-qbtx) label expansion decision](https://sec-api.dev/pdufa/infliximab-qbtx) | PFE |  | completed, approved | "BLA761072 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20200116, review_priority STANDARD; sponsor_name PFIZER INC; product IXIFI (INFLIXIMAB-QBTX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761072%22)) |
| February 27, 2020 | [Nurtec Odt (rimegepant sulfate) FDA approval](https://sec-api.dev/pdufa/rimegepant) | PFE |  | completed, approved | "NDA212728 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200227, review_priority PRIORITY; sponsor_name PFIZER; product NURTEC ODT (RIMEGEPANT SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212728%22)) |
| March 9, 2020 | [Talzenna (talazoparib tosylate) label expansion decision](https://sec-api.dev/pdufa/talazoparib) | PFE |  | completed, approved | "NDA211651 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20200309, review_priority STANDARD; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211651%22)) |
| March 17, 2020 | [Mannitol 25% (mannitol) label expansion decision](https://sec-api.dev/pdufa/mannitol) | PFE |  | completed, approved | "NDA016269 SUPPL-56 (Efficacy): submission_status AP, submission_status_date 20200317, review_priority STANDARD; sponsor_name HOSPIRA; product MANNITOL 25% (MANNITOL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA016269%22)) |
| April 17, 2020 | [Tukysa (tucatinib) FDA approval](https://sec-api.dev/pdufa/tucatinib) | PFE |  | completed, approved | "NDA213411 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200417, review_priority PRIORITY; sponsor_name SEAGEN; product TUKYSA (TUCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213411%22)) |
| May 26, 2020 | [Zosyn (piperacillin sodium; tazobactam sodium) label expansion decision](https://sec-api.dev/pdufa/piperacillin-tazobactam) | PFE |  | completed, approved | "NDA050684 SUPPL-96 (Efficacy): submission_status AP, submission_status_date 20200526, review_priority STANDARD; sponsor_name WYETH PHARMS; product ZOSYN (PIPERACILLIN SODIUM; TAZOBACTAM SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA050684%22)) |
| May 26, 2020 | [Ruxience (rituximab-pvvr) label expansion decision](https://sec-api.dev/pdufa/rituximab-pvvr) | PFE |  | completed, approved | "BLA761103 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20200526, review_priority STANDARD; sponsor_name PFIZER INC; product RUXIENCE (RITUXIMAB-PVVR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761103%22)) |
| June 4, 2020 | [Inlyta (axitinib) label expansion decision](https://sec-api.dev/pdufa/axitinib) | PFE |  | completed, approved | "NDA202324 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20200604, review_priority PRIORITY; sponsor_name PF PRISM CV; product INLYTA (AXITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202324%22)) |
| June 10, 2020 | [Nyvepria (pegfilgrastim-apgf) FDA approval](https://sec-api.dev/pdufa/pegfilgrastim-apgf) | PFE |  | completed, approved | "BLA761111 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20200610, review_priority STANDARD; sponsor_name HOSPIRA INC; product NYVEPRIA (PEGFILGRASTIM-APGF)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761111%22)) |
| June 16, 2020 | [Mylotarg (gemtuzumab ozogamicin) label expansion decision](https://sec-api.dev/pdufa/gemtuzumab-ozogamicin) | PFE |  | completed, approved | "BLA761060 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20200616, review_priority PRIORITY; sponsor_name WYETH PHARMS INC; product MYLOTARG (GEMTUZUMAB OZOGAMICIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761060%22)) |
| June 30, 2020 | [Retacrit (epoetin alfa-epbx) label expansion decision](https://sec-api.dev/pdufa/epoetin-alfa-epbx) | PFE |  | completed, approved | "BLA125545 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20200630, review_priority STANDARD; sponsor_name HOSPIRA INC; product RETACRIT (EPOETIN ALFA-EPBX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125545%22)) |
| September 25, 2020 | [Xeljanz (tofacitinib citrate) FDA approval](https://sec-api.dev/pdufa/tofacitinib) | PFE |  | completed, approved | "NDA213082 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20200925, review_priority PRIORITY; sponsor_name PFIZER; product XELJANZ (TOFACITINIB CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213082%22)) |
| September 25, 2020 | [Xeljanz (tofacitinib citrate) label expansion decision](https://sec-api.dev/pdufa/tofacitinib) | PFE |  | completed, approved | "NDA203214 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20200925, review_priority PRIORITY; sponsor_name PF PRISM CV; product XELJANZ (TOFACITINIB CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203214%22)) |
| October 22, 2020 | [Talzenna (talazoparib tosylate) label expansion decision](https://sec-api.dev/pdufa/talazoparib) | PFE |  | completed, approved | "NDA211651 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20201022, review_priority STANDARD; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211651%22)) |
| December 4, 2020 | [Depo-Provera (medroxyprogesterone acetate) label expansion decision](https://sec-api.dev/pdufa/medroxyprogesterone) | PFE |  | completed, approved | "NDA020246 SUPPL-62 (Efficacy): submission_status AP, submission_status_date 20201204, review_priority STANDARD; sponsor_name PFIZER; product DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020246%22)) |
| January 14, 2021 | [Xalkori (crizotinib) label expansion decision](https://sec-api.dev/pdufa/crizotinib) | PFE |  | completed, approved | "NDA202570 SUPPL-30 (Efficacy): submission_status AP, submission_status_date 20210114, review_priority PRIORITY; sponsor_name PF PRISM CV; product XALKORI (CRIZOTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202570%22)) |
| February 9, 2021 | [Zirabev (bevacizumab-bvzr) label expansion decision](https://sec-api.dev/pdufa/bevacizumab-bvzr) | PFE |  | completed, approved | "BLA761099 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20210209, review_priority STANDARD; sponsor_name PFIZER INC; product ZIRABEV (BEVACIZUMAB-BVZR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761099%22)) |
| March 3, 2021 | [Lorbrena (lorlatinib) label expansion decision](https://sec-api.dev/pdufa/lorlatinib) | PFE |  | completed, approved | "NDA210868 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20210303, review_priority PRIORITY; sponsor_name PFIZER; product LORBRENA (LORLATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210868%22)) |
| March 29, 2021 | [Methotrexate Preservative Free (methotrexate) label expansion decision](https://sec-api.dev/pdufa/methotrexate) | PFE |  | completed, approved | "NDA011719 SUPPL-131 (Efficacy): submission_status AP, submission_status_date 20210329, review_priority STANDARD; sponsor_name HOSPIRA; product METHOTREXATE PRESERVATIVE FREE (METHOTREXATE SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA011719%22)) |
| April 29, 2021 | [Morphine Sulfate (morphine sulfate) label expansion decision](https://sec-api.dev/pdufa/morphine) | PFE |  | completed, approved | "NDA202515 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20210429, review_priority STANDARD; sponsor_name HOSPIRA INC; product MORPHINE SULFATE (MORPHINE SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202515%22)) |
| May 14, 2021 | [Bosulif (bosutinib monohydrate) label expansion decision](https://sec-api.dev/pdufa/bosutinib) | PFE |  | completed, approved | "NDA203341 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20210514, review_priority PRIORITY; sponsor_name PF PRISM CV; product BOSULIF (BOSUTINIB MONOHYDRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203341%22)) |
| May 27, 2021 | [Nurtec Odt (rimegepant sulfate) label expansion decision](https://sec-api.dev/pdufa/rimegepant) | PFE |  | completed, approved | "NDA212728 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20210527, review_priority STANDARD; sponsor_name PFIZER; product NURTEC ODT (RIMEGEPANT SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212728%22)) |
| June 17, 2021 | [Toviaz (fesoterodine fumarate) label expansion decision](https://sec-api.dev/pdufa/fesoterodine) | PFE |  | completed, approved | "NDA022030 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20210617, review_priority PRIORITY; sponsor_name PFIZER; product TOVIAZ (FESOTERODINE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022030%22)) |
| June 21, 2021 | [Daptomycin (daptomycin) FDA approval](https://sec-api.dev/pdufa/daptomycin) | PFE |  | completed, approved | "NDA210282 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20210621, review_priority STANDARD; sponsor_name HOSPIRA; product DAPTOMYCIN (DAPTOMYCIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210282%22)) |
| September 9, 2021 | [Talzenna (talazoparib tosylate) label expansion decision](https://sec-api.dev/pdufa/talazoparib) | PFE |  | completed, approved | "NDA211651 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20210909, review_priority STANDARD; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211651%22)) |
| September 20, 2021 | [Tivdak (tisotumab vedotin-tftv) FDA approval](https://sec-api.dev/pdufa/tisotumab-vedotin-tftv) | PFE |  | completed, approved | "BLA761208 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210920, review_priority PRIORITY; sponsor_name SEAGEN; product TIVDAK (TISOTUMAB VEDOTIN-TFTV)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761208%22)) |
| November 15, 2021 | [Ruxience (rituximab-pvvr) label expansion decision](https://sec-api.dev/pdufa/rituximab-pvvr) | PFE |  | completed, approved | "BLA761103 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20211115, review_priority STANDARD; sponsor_name PFIZER INC; product RUXIENCE (RITUXIMAB-PVVR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761103%22)) |
| December 14, 2021 | [Xeljanz (tofacitinib citrate) label expansion decision](https://sec-api.dev/pdufa/tofacitinib) | PFE |  | completed, approved | "NDA203214 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20211214, review_priority STANDARD; sponsor_name PF PRISM CV; product XELJANZ (TOFACITINIB CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203214%22)) |
| January 14, 2022 | [Cibinqo (abrocitinib) FDA approval](https://sec-api.dev/pdufa/abrocitinib) | PFE | To treat refractory, moderate-to-severe atopic dermatitis | completed, approved | "Cibinqo \| abrocitinib \| 1/14/2022 \| To treat refractory, moderate-to-severe atopic dermatitisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| January 21, 2022 | [Ngenla (somatrogon-ghla) complete response letter (CRL)](https://sec-api.dev/pdufa/somatrogon-ghla) | PFE |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761184_2023_Orig1s000OtherActionLtrs.pdf%22)) |
| April 11, 2022 | [Nurtec Odt (rimegepant sulfate) label expansion decision](https://sec-api.dev/pdufa/rimegepant) | PFE |  | completed, approved | "NDA212728 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20220411, review_priority STANDARD; sponsor_name PFIZER; product NURTEC ODT (RIMEGEPANT SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212728%22)) |
| May 2, 2022 | [VELCADE® (bortezomib) FDA approval](https://sec-api.dev/pdufa/bortezomib) | PFE |  | completed, approved | "NDA209191 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20220502, review_priority STANDARD; sponsor_name HOSPIRA; product BORTEZOMIB (BORTEZOMIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209191%22)) |
| June 10, 2022 | [Pemetrexed Ditromethamine (pemetrexed ditromethamine) FDA approval](https://sec-api.dev/pdufa/pemetrexed-ditromethamine) | PFE |  | completed, approved | "NDA208746 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220610, review_priority STANDARD; sponsor_name HOSPIRA; product PEMETREXED DITROMETHAMINE (PEMETREXED DITROMETHAMINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208746%22)) |
| June 22, 2022 | [Alimta (pemetrexed) FDA approval](https://sec-api.dev/pdufa/pemetrexed) | PFE |  | completed, approved | "NDA214218 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20220622, review_priority STANDARD; sponsor_name HOSPIRA; product PEMETREXED DISODIUM (PEMETREXED DISODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214218%22)) |
| July 14, 2022 | [Xalkori (crizotinib) label expansion decision](https://sec-api.dev/pdufa/crizotinib) | PFE |  | completed, approved | "NDA202570 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20220714, review_priority PRIORITY; sponsor_name PF PRISM CV; product XALKORI (CRIZOTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202570%22)) |
| July 29, 2022 | [Abrilada (adalimumab-afzb) label expansion decision](https://sec-api.dev/pdufa/adalimumab-afzb) | PFE |  | completed, approved | "BLA761118 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20220729, review_priority STANDARD; sponsor_name PFIZER INC; product ABRILADA (ADALIMUMAB-AFZB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761118%22)) |
| September 22, 2022 | [Inlyta (axitinib) label expansion decision](https://sec-api.dev/pdufa/axitinib) | PFE |  | completed, approved | "NDA202324 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20220922, review_priority STANDARD; sponsor_name PF PRISM CV; product INLYTA (AXITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202324%22)) |
| December 9, 2022 | [VELCADE® (bortezomib) label expansion decision](https://sec-api.dev/pdufa/bortezomib) | PFE |  | completed, approved | "NDA209191 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20221209, review_priority STANDARD; sponsor_name HOSPIRA; product BORTEZOMIB (BORTEZOMIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209191%22)) |
| December 13, 2022 | [IBRANCE® (palbociclib) label expansion decision](https://sec-api.dev/pdufa/palbociclib) | PFE |  | completed, approved | "NDA212436 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20221213, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22)) |
| December 15, 2022 | [BENDEKA (bendamustine) FDA approval](https://sec-api.dev/pdufa/bendamustine) | PFE |  | completed, approved | "NDA211530 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20221215, review_priority STANDARD; sponsor_name HOSPIRA; product BENDAMUSTINE HYDROCHLORIDE (BENDAMUSTINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211530%22)) |
| December 16, 2022 | [IGALMI® (dexmedetomidine) label expansion decision](https://sec-api.dev/pdufa/dexmedetomidine) | PFE |  | completed, approved | "NDA021038 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20221216, review_priority STANDARD; sponsor_name HOSPIRA; product PRECEDEX (DEXMEDETOMIDINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021038%22)) |
| January 19, 2023 | [Tukysa (tucatinib) label expansion decision](https://sec-api.dev/pdufa/tucatinib) | PFE |  | completed, approved | "NDA213411 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20230119, review_priority PRIORITY; sponsor_name SEAGEN; product TUKYSA (TUCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213411%22)) |
| February 9, 2023 | [Cibinqo (abrocitinib) label expansion decision](https://sec-api.dev/pdufa/abrocitinib) | PFE |  | completed, approved | "NDA213871 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20230209, review_priority PRIORITY; sponsor_name PFIZER; product CIBINQO (ABROCITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213871%22)) |
| March 9, 2023 | [Zavzpret ® (zavegepant) FDA approval](https://sec-api.dev/pdufa/zavegepant) | PFE | To treat migraineDrug Trails Snapshot | completed, approved | "Zavzpret \| zavegepant \| 3/9/2023 \| To treat migraineDrug Trails Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| May 25, 2023 | [PAXLOVID® (nirmatrelvir-ritonavir) FDA approval](https://sec-api.dev/pdufa/nirmatrelvir-ritonavir) | PFE |  | completed, approved | "Paxlovid \| nirmatrelvir, ritonavir \| 5/25/2023 \| To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19Press ReleaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| June 14, 2023 | [Abrilada (adalimumab-afzb) label expansion decision](https://sec-api.dev/pdufa/adalimumab-afzb) | PFE |  | completed, approved | "BLA761118 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20230614, review_priority STANDARD; sponsor_name PFIZER INC; product ABRILADA (ADALIMUMAB-AFZB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761118%22)) |
| June 20, 2023 | [Talzenna (talazoparib tosylate) label expansion decision](https://sec-api.dev/pdufa/talazoparib) | PFE |  | completed, approved | "NDA211651 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20230620, review_priority PRIORITY; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211651%22)) |
| June 23, 2023 | [Litfulo (ritlecitinib tosylate) FDA approval](https://sec-api.dev/pdufa/ritlecitinib) | PFE | To treat severely patchy hair loss | completed, approved | "Litfulo \| ritlecitinib \| 6/23/2023 \| To treat severely patchy hair lossDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| June 27, 2023 | [Ngenla (somatrogon-ghla) FDA approval](https://sec-api.dev/pdufa/somatrogon-ghla) | PFE | To treat growth failure due to inadequate secretion of endogenous growth hormone | completed, approved | "Ngenla \| somatrogon-ghla \| 6/27/2023 \| To treat growth failure due to inadequate secretion of endogenous growth hormoneDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| August 14, 2023 | [Elrexfio (elranatamab) FDA approval](https://sec-api.dev/pdufa/elranatamab) | PFE |  | completed, approved | "Elrexfio \| elranatamab-bcmm \| 8/14/2023 \| To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapyDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| September 6, 2023 | [IBRANCE® (palbociclib) label expansion decision](https://sec-api.dev/pdufa/palbociclib) | PFE |  | completed, approved | "NDA212436 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20230906, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22)) |
| September 7, 2023 | [Xalkori (crizotinib) FDA approval](https://sec-api.dev/pdufa/crizotinib) | PFE |  | completed, approved | "NDA217581 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20230907, review_priority STANDARD; sponsor_name PF PRISM CV; product XALKORI (CRIZOTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217581%22)) |
| September 7, 2023 | [Xalkori (crizotinib) label expansion decision](https://sec-api.dev/pdufa/crizotinib) | PFE |  | completed, approved | "NDA202570 SUPPL-36 (Efficacy): submission_status AP, submission_status_date 20230907, review_priority STANDARD; sponsor_name PF PRISM CV; product XALKORI (CRIZOTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202570%22)) |
| September 26, 2023 | [Bosulif (bosutinib monohydrate) FDA approval](https://sec-api.dev/pdufa/bosutinib) | PFE |  | completed, approved | "NDA217729 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20230926, review_priority PRIORITY; sponsor_name PF PRISM CV; product BOSULIF (BOSUTINIB MONOHYDRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217729%22)) |
| September 26, 2023 | [Bosulif (bosutinib monohydrate) label expansion decision](https://sec-api.dev/pdufa/bosutinib) | PFE |  | completed, approved | "NDA203341 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20230926, review_priority PRIORITY; sponsor_name PF PRISM CV; product BOSULIF (BOSUTINIB MONOHYDRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203341%22)) |
| October 4, 2023 | [Abrilada (adalimumab-afzb) label expansion decision](https://sec-api.dev/pdufa/adalimumab-afzb) | PFE |  | completed, approved | "BLA761118 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20231004, review_priority STANDARD; sponsor_name PFIZER INC; product ABRILADA (ADALIMUMAB-AFZB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761118%22)) |
| October 12, 2023 | [Velsipity (etrasimod arginine) FDA approval](https://sec-api.dev/pdufa/etrasimod-arginine) | PFE | To treat moderately to severely active ulcerative colitis in adults | completed, approved | "Velsipity \| etrasimod \| 10/12/2023 \| To treat moderately to severely active ulcerative colitis in adultsDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| December 14, 2023 | [Cibinqo (abrocitinib) label expansion decision](https://sec-api.dev/pdufa/abrocitinib) | PFE |  | completed, approved | "NDA213871 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20231214, review_priority STANDARD; sponsor_name PFIZER; product CIBINQO (ABROCITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213871%22)) |
| March 6, 2024 | [Besponsa (inotuzumab ozogamicin) label expansion decision](https://sec-api.dev/pdufa/inotuzumab-ozogamicin) | PFE |  | completed, approved | "BLA761040 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20240306, review_priority PRIORITY; sponsor_name WYETH PHARMS INC; product BESPONSA (INOTUZUMAB OZOGAMICIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761040%22)) |
| March 7, 2024 | [Talzenna (talazoparib tosylate) FDA approval](https://sec-api.dev/pdufa/talazoparib) | PFE |  | completed, approved | "NDA217439 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20240307, review_priority STANDARD; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217439%22)) |
| April 29, 2024 | [Tivdak (tisotumab vedotin-tftv) label expansion decision](https://sec-api.dev/pdufa/tisotumab-vedotin-tftv) | PFE |  | completed, approved | "BLA761208 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20240429, review_priority PRIORITY; sponsor_name SEAGEN; product TIVDAK (TISOTUMAB VEDOTIN-TFTV)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761208%22)) |
| August 12, 2024 | [Protonix Iv (pantoprazole sodium) label expansion decision](https://sec-api.dev/pdufa/pantoprazole) | PFE |  | completed, approved | "NDA020988 SUPPL-70 (Efficacy): submission_status AP, submission_status_date 20240812, review_priority STANDARD; sponsor_name WYETH PHARMS; product PROTONIX IV (PANTOPRAZOLE SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020988%22)) |
| October 11, 2024 | [Hympavzi (marstacimab-hncq) FDA approval](https://sec-api.dev/pdufa/marstacimab-hncq) | PFE | To prevent or reduce bleeding episodes related to hemophilia A or BPress Release | completed, approved | "Hympavzi \| marstacimab-hncq \| 10/11/2024 \| To prevent or reduce bleeding episodes related to hemophilia A or BPress ReleaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| October 15, 2024 | [Fragmin (dalteparin sodium) label expansion decision](https://sec-api.dev/pdufa/dalteparin) | PFE |  | completed, approved | "NDA020287 SUPPL-80 (Efficacy): submission_status AP, submission_status_date 20241015, review_priority STANDARD; sponsor_name PFIZER; product FRAGMIN (DALTEPARIN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020287%22)) |
| January 17, 2025 | [Nda219112 complete response letter (CRL)](https://sec-api.dev/pdufa/nda219112) | PFE |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219112_20250117.pdf%22)) |
| January 31, 2025 | [PAXLOVID® (nirmatrelvir-ritonavir) label expansion decision](https://sec-api.dev/pdufa/nirmatrelvir-ritonavir) | PFE |  | completed, approved | "NDA217188 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20250131, review_priority PRIORITY; sponsor_name PFIZER; product PAXLOVID (COPACKAGED) (NIRMATRELVIR; RITONAVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217188%22)) |
| February 4, 2025 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "NEW YORK, Tuesday, February 4, 2025 — Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance(5) provided on December 17, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800325000017/pfe-12312024xex99.htm)) |
| February 21, 2025 | [Xeljanz (tofacitinib citrate) label expansion decision](https://sec-api.dev/pdufa/tofacitinib) | PFE |  | completed, approved | "NDA203214 SUPPL-38 (Efficacy): submission_status AP, submission_status_date 20250221, review_priority STANDARD; sponsor_name PF PRISM CV; product XELJANZ (TOFACITINIB CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203214%22)) |
| April 23, 2025 | [IBRANCE® (palbociclib) label expansion decision](https://sec-api.dev/pdufa/palbociclib) | PFE |  | completed, approved | "NDA212436 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20250423, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22)) |
| April 29, 2025 | [Revlimid® (lenalidomide) label expansion decision](https://sec-api.dev/pdufa/lenalidomide) | PFE |  | completed, approved | "Announced the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for Adcetris in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma, after two or more lines of systemic therapy who are not eligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or chimeric antigen receptor (CAR) T-cell therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800325000111/pfe-03302025xex99.htm)) |
| April 29, 2025 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800325000111/pfe-03302025xex99.htm)) |
| May 21, 2025 | [Talzenna (talazoparib tosylate) FDA advisory committee meeting](https://sec-api.dev/pdufa/talazoparib) | PFE |  | completed, negative | "On the afternoon of May 21, 2025, the Committee will discuss supplemental new drug application (sNDA) 211651/S-013, for TALZENNA (talazoparib) capsules, submitted by Pfizer Inc. The proposed indication (use) is in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC)." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025)) |
| May 30, 2025 | [Zavzpret ® (zavegepant) primary completion](https://sec-api.dev/pdufa/zavegepant) | PFE | Migraine | completed | "NCT05989048 (A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05989048)) |
| June 5, 2025 | [PF-06823859 primary completion](https://sec-api.dev/pdufa/pf-06823859) | PFE | Lupus Erythematosus, Systemic; Lupus Erythematosus, Cutaneous | withdrawn | "NCT05879718 (A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-08-11." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05879718)) |
| June 11, 2025 | [Rsvpref vaccine primary completion](https://sec-api.dev/pdufa/rsvpref-vaccine) | PFE | Respiratory Syncytial Virus | completed | "NCT06325657 (A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06325657)) |
| June 12, 2025 | [Talzenna (talazoparib tosylate) label expansion decision](https://sec-api.dev/pdufa/talazoparib) | PFE |  | completed, approved | "NDA217439 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20250612, review_priority PRIORITY; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217439%22)) |
| July 3, 2025 | [Met097 injection primary completion](https://sec-api.dev/pdufa/met097) | PFE | Obesity; Overweight or Obesity | completed | "NCT06712836 (A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-03 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-08-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06712836)) |
| July 10, 2025 | [Elrexfio (elranatamab) label expansion decision](https://sec-api.dev/pdufa/elranatamab) | PFE |  | completed, approved | "BLA761345 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20250710, review_priority STANDARD; sponsor_name PFIZER INC; product ELREXFIO (ELRANATAMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761345%22)) |
| July 10, 2025 | [PF-07220060 primary completion](https://sec-api.dev/pdufa/pf-07220060) | PFE | Breast Cancer | completed | "NCT06465368 (A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-10 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-07-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465368)) |
| July 21, 2025 | [VLA15 primary completion](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | completed | "NCT05634811 (Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-21 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05634811)) |
| August 5, 2025 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800325000136/pfe-06292025xex99.htm)) |
| August 25, 2025 | [Nurtec Odt (rimegepant sulfate) primary completion](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | completed | "NCT05810038 (A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-25 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-09-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05810038)) |
| September 5, 2025 | [Tukysa (tucatinib) primary completion](https://sec-api.dev/pdufa/tucatinib) | PFE | HER2 Positive Breast Cancer | completed | "NCT05132582 (A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-09-05 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05132582)) |
| September 16, 2025 | [IBRANCE® (palbociclib) label expansion decision](https://sec-api.dev/pdufa/palbociclib) | PFE |  | completed, approved | "NDA212436 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20250916, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22)) |
| September 20, 2025 | [20-valent pneumococcal conjugate vaccine primary completion](https://sec-api.dev/pdufa/20-valent-pneumococcal-conjugate-vaccine) | PFE | Pneumococcal Disease | completed | "NCT05512819 (A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-20 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05512819)) |
| September 24, 2025 | [Fordadistrogene movaparvovec primary completion](https://sec-api.dev/pdufa/fordadistrogene-movaparvovec) | PFE | Duchenne Muscular Dystrophy | withdrawn | "NCT05689164 (A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-09-24 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05689164)) |
| September 30, 2025 | [Respiratory syncytial virus prefusion f subunit vaccine primary completion](https://sec-api.dev/pdufa/respiratory-syncytial-virus-prefusion-f-subunit-vaccine) | PFE | Respiratory Syncytial Virus (RSV) | completed | "NCT06890416 (A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890416)) |
| October 3, 2025 | [Fordadistrogene movaparvovec primary completion](https://sec-api.dev/pdufa/fordadistrogene-movaparvovec) | PFE | Muscular Dystrophy, Duchenne | withdrawn | "NCT05429372 (Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-03 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05429372)) |
| October 16, 2025 | [Xeljanz (tofacitinib citrate) label expansion decision](https://sec-api.dev/pdufa/tofacitinib) | PFE |  | completed, approved | "NDA203214 SUPPL-39 (Efficacy): submission_status AP, submission_status_date 20251016, review_priority STANDARD; sponsor_name PF PRISM CV; product XELJANZ (TOFACITINIB CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203214%22)) |
| October 23, 2025 | [PF-07976016 primary completion](https://sec-api.dev/pdufa/pf-07976016) | PFE | Obesity | completed | "NCT06717425 (A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-23 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06717425)) |
| November 4, 2025 | [PFIZER INC label expansion decision](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed, approved | "Pfizer and BioNTech announced the FDA approved the supplemental Biologics License Application (sBLA) for the companies' LP.8.1-adapted monovalent COVID-19 vaccine for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800325000149/pfe-09282025xex99.htm)) |
| November 4, 2025 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800325000149/pfe-09282025xex99.htm)) |
| November 7, 2025 | [Inclacumab primary completion](https://sec-api.dev/pdufa/inclacumab) | PFE |  | withdrawn | "NCT05348915 (A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-07 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05348915)) |
| December 16, 2025 | [PFIZER INC primary completion](https://sec-api.dev/companies/pfe/catalysts) | PFE | Esophagitis | withdrawn | "NCT04821310 (Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-12-16 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04821310)) |
| December 16, 2025 | [Met097 injection primary completion](https://sec-api.dev/pdufa/met097) | PFE | Obesity; Overweight or Obesity | completed | "NCT06973720 (A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-16 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06973720)) |
| December 22, 2025 | [Cibinqo (abrocitinib) primary completion](https://sec-api.dev/pdufa/abrocitinib) | PFE | Dermatitis, Atopic | completed | "NCT03422822 (Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-22 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03422822)) |
| December 29, 2025 | [Met097 injection primary completion](https://sec-api.dev/pdufa/met097) | PFE | Obesity in Diabetes; Type 2 Diabetes Mellitus (T2DM) | completed | "NCT06897202 (A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-29 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06897202)) |
| 2026 | [PF-08634404 trial start](https://sec-api.dev/pdufa/pf-08634404) | PFE |  | scheduled | "Additionally, our guidance reflects our expectation for a continued focus on prioritization in key therapeutic areas as well as our plan to start approximately 20 key pivotal trials in 2026, including ten pivotal trials for ultra-long-acting obesity assets acquired from Metsera and four pivotal trials for PF-08634404 (a PD-1 x VEGF bispecific antibody in-licensed from 3SBio)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000005/pfe-12312025xex99.htm)) |
| January 7, 2026 | [VLA15 primary completion](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | completed | "NCT05477524 (An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-07 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05477524)) |
| January 12, 2026 | [Pf-07220060 cdk4 inhibitor primary completion](https://sec-api.dev/pdufa/pf-07220060-cdk4-inhibitor) | PFE | Advanced or Metastatic Breast Cancer | completed | "NCT06105632 (A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06105632)) |
| January 23, 2026 | [Brentuximab vedotin primary completion](https://sec-api.dev/pdufa/brentuximab-vedotin) | PFE | Diffuse Large B-cell Lymphoma | completed | "NCT04404283 (Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-23 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04404283)) |
| February 2, 2026 | [Encorafenib primary completion](https://sec-api.dev/pdufa/encorafenib) | PFE | Melanoma | withdrawn | "NCT05926960 (A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-02-02 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05926960)) |
| February 3, 2026 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "NEW YORK, Tuesday, February 3, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000005/pfe-12312025xex99.htm)) |
| February 3, 2026 | [KEYTRUDA® (pembrolizumab) FDA approval](https://sec-api.dev/pdufa/pembrolizumab) | PFE |  | completed, approved | "Pfizer and Astellas announced the U.S. Food and Drug Administration (FDA) approved Padcev in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as neoadjuvant treatment and then continued after cystectomy (surgery) as adjuvant treatment for adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000005/pfe-12312025xex99.htm)) |
| February 3, 2026 | [Brentuximab vedotin primary completion](https://sec-api.dev/pdufa/brentuximab-vedotin) | PFE | Melanoma; Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck | completed | "NCT04609566 (Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-03 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04609566)) |
| February 5, 2026 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo | completed | "NCT05583526 (A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-05 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05583526)) |
| February 9, 2026 | [Pg4 primary completion](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | completed | "NCT06531538 (A Study to Learn About How a New Pneumococcal Vaccine Works in Children): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-09 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06531538)) |
| February 18, 2026 | [Talazoparib plus enzalutamide primary completion](https://sec-api.dev/pdufa/talazoparib-plus-enzalutamide) | PFE | Prostate Cancer | completed | "NCT04821622 (Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-18 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04821622)) |
| February 26, 2026 | [Elrexfio (elranatamab) primary completion](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | completed | "NCT05020236 (A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-02-26 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05020236)) |
| March 6, 2026 | [Xeljanz (tofacitinib citrate) label expansion decision](https://sec-api.dev/pdufa/tofacitinib) | PFE |  | completed, approved | "NDA203214 SUPPL-41 (Efficacy): submission_status AP, submission_status_date 20260306, review_priority STANDARD; sponsor_name PF PRISM CV; product XELJANZ (TOFACITINIB CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203214%22)) |
| March 20, 2026 | [Tisotumab vedotin primary completion](https://sec-api.dev/pdufa/tisotumab-vedotin) | PFE | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Exocrine Pancreatic Cancer | completed | "NCT03485209 (Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-20 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03485209)) |
| March 27, 2026 | [Disitamab vedotin primary completion](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Endometrial Neoplasms | completed | "NCT06003231 (A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-27 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06003231)) |
| Q2 2026 | [PFIZER INC PDUFA date](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | scheduled | "The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm)) |
| May 5, 2026 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm)) |
| May 5, 2026 | [KEYTRUDA® (pembrolizumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/pembrolizumab) | PFE | muscle-invasive bladder cancer | completed | "Pfizer and Astellas Pharma Inc. announced the FDA accepted for priority review a sBLA for perioperative (before and after surgery) Padcev in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as treatment for patients with muscle-invasive bladder cancer (MIBC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm)) |
| May 7, 2026 | [VLA15 topline data readout](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | completed | "NCT05634811 (Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-21 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05634811?tab=results)) |
| May 18, 2026 | [Sigvotatug vedotin primary completion](https://sec-api.dev/pdufa/sigvotatug-vedotin) | PFE | Carcinoma, Non-Small-Cell Lung | completed | "NCT06012435 (A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-18 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06012435)) |
| May 22, 2026 | [Zavzpret ® (zavegepant) topline data readout](https://sec-api.dev/pdufa/zavegepant) | PFE | Migraine | completed | "NCT05989048 (A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05989048?tab=results)) |
| June 5, 2026 | [Hympavzi (marstacimab-hncq) label expansion decision](https://sec-api.dev/pdufa/marstacimab-hncq) | PFE |  | completed, approved | "BLA761369 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20260605, review_priority PRIORITY; sponsor_name PFIZER INC; product HYMPAVZI (MARSTACIMAB-HNCQ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761369%22)) |
| June 19, 2026 | [Encorafenib primary completion](https://sec-api.dev/pdufa/encorafenib) | PFE | Metastatic Colorectal Cancer | completed | "NCT05217446 (A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-19 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05217446)) |
| June 24, 2026 | [IBRANCE® (palbociclib) label expansion decision](https://sec-api.dev/pdufa/palbociclib) | PFE |  | completed, approved | "NDA212436 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20260624, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22)) |
| July 2, 2026 | [Rsvpref vaccine topline data readout](https://sec-api.dev/pdufa/rsvpref-vaccine) | PFE | Respiratory Syncytial Virus | completed | "NCT06325657 (A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06325657?tab=results)) |
| July 15, 2026 | [PF-07220060 topline data readout](https://sec-api.dev/pdufa/pf-07220060) | PFE | Breast Cancer | completed | "NCT06465368 (A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-10 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-07-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465368?tab=results)) |
| July 23, 2026 | [Pf-06838435 (formerly spk-9001) primary completion](https://sec-api.dev/pdufa/pf-06838435-formerly-spk-9001) | PFE | Hemophilia B | withdrawn | "NCT03307980 (Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-07-23 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03307980)) |
| July 2026 | [Nirmatrelvir primary completion](https://sec-api.dev/pdufa/nirmatrelvir) | PFE | COVID-19 | delayed | "NCT05261139 (EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-07-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05261139)) |
| August 4, 2026 | [KEYTRUDA® (pembrolizumab) FDA approval](https://sec-api.dev/pdufa/pembrolizumab) | PFE | muscle-invasive bladder cancer | completed, approved | "Pfizer and Astellas Pharma Inc. announced FDA approval of Padcev plus pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as neoadjuvant and adjuvant (before and after surgery) treatment for adult patients with muscle-invasive bladder cancer (MIBC) regardless of cisplatin eligibility." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm)) |
| August 4, 2026 | [KANJINTI® (trastuzumab) FDA approval](https://sec-api.dev/pdufa/trastuzumab) | PFE |  | completed, approved | "Announced FDA approval of Ibrance in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metastatic breast cancer (MBC) following induction treatment based on data from the collaborative Phase 3 PATINA trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm)) |
| August 4, 2026 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm)) |
| August 4, 2026 | [PFIZER INC label expansion decision](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed, approved | "Announced the U.S. Food and Drug Administration (FDA) approved an expanded indication for Hympavzi to include the treatment of patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm)) |
| August 17, 2026 | [Cisplatin PDUFA date](https://sec-api.dev/pdufa/cisplatin) | PFE |  | scheduled | "The FDA has set a PDUFA target action date of August 17, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm)) |
| August 25, 2026 | [Rsvpref primary completion](https://sec-api.dev/pdufa/rsvpref) | PFE | Respiratory Syncytial Virus (RSV) | completed | "NCT07543380 (A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-25 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07543380)) |
| Aug to Nov 2026 | [Rsvpref topline data readout](https://sec-api.dev/pdufa/rsvpref) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07543380 (A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-25 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07543380)) |
| August 26, 2026 | [Elrexfio (elranatamab) primary completion](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | completed | "NCT06152575 (MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-08-26 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06152575)) |
| Aug to Nov 2026 | [Elrexfio (elranatamab) topline data readout](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | scheduled | "NCT06152575 (MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-08-26 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06152575)) |
| August 28, 2026 | [Met097 injection topline data readout](https://sec-api.dev/pdufa/met097) | PFE | Obesity; Overweight or Obesity | completed | "NCT06712836 (A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-03 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-08-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06712836?tab=results)) |
| September 3, 2026 | [Nurtec Odt (rimegepant sulfate) topline data readout](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | completed | "NCT05810038 (A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-25 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-09-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05810038?tab=results)) |
| September 23, 2026 | [PF-06835375 primary completion](https://sec-api.dev/pdufa/pf-06835375) | PFE | Primary Immune Thrombocytopenia | withdrawn | "NCT05070845 (Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-23 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05070845)) |
| September 29, 2026 | [Tukysa (tucatinib) topline data readout](https://sec-api.dev/pdufa/tucatinib) | PFE | HER2 Positive Breast Cancer | completed | "NCT05132582 (A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-09-05 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05132582?tab=results)) |
| Oct 2026 to Jan 2027 | [Encorafenib topline data readout](https://sec-api.dev/pdufa/encorafenib) | PFE | Melanoma | scheduled | "NCT04657991 (A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04657991)) |
| October 7, 2026 | [Tukysa (tucatinib) label expansion decision](https://sec-api.dev/pdufa/tucatinib) | PFE |  | completed, approved | "NDA213411 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20261007, review_priority STANDARD; sponsor_name SEAGEN; product TUKYSA (TUCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213411%22)) |
| October 9, 2026 | [PF-07868489 primary completion](https://sec-api.dev/pdufa/pf-07868489) | PFE | Pulmonary Hypertension | withdrawn | "NCT07073820 (A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-10-09 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07073820)) |
| October 21, 2026 | [Brentuximab vedotin topline data readout](https://sec-api.dev/pdufa/brentuximab-vedotin) | PFE | Diffuse Large B-cell Lymphoma | completed | "NCT04404283 (Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-23 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04404283?tab=results)) |
| October 26, 2026 | [Talzenna (talazoparib tosylate) label expansion decision](https://sec-api.dev/pdufa/talazoparib) | PFE |  | completed, approved | "NDA217439 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20261026, review_priority PRIORITY; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217439%22)) |
| October 2026 | [Encorafenib primary completion](https://sec-api.dev/pdufa/encorafenib) | PFE | Melanoma | delayed | "NCT04657991 (A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04657991)) |
| Nov 2026 to Feb 2027 | [Pf-07275315 dose 1 topline data readout](https://sec-api.dev/pdufa/pf-07275315) | PFE | Atopic Dermatitis | scheduled | "NCT05995964 (A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-12 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05995964)) |
| Nov 2026 to Feb 2027 | [Nurtec Odt (rimegepant sulfate) topline data readout](https://sec-api.dev/pdufa/rimegepant) | PFE | Menstrual Migraine | scheduled | "NCT06641466 (A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-29 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06641466)) |
| November 3, 2026 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000125/pfe-9272026xex99.htm)) |
| November 2026 | [Pf-07275315 dose 1 primary completion](https://sec-api.dev/pdufa/pf-07275315) | PFE | Atopic Dermatitis | scheduled | "NCT05995964 (A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-12 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05995964)) |
| November 2026 | [Nurtec Odt (rimegepant sulfate) primary completion](https://sec-api.dev/pdufa/rimegepant) | PFE | Menstrual Migraine | scheduled | "NCT06641466 (A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-29 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06641466)) |
| Dec 2026 to Mar 2027 | [Pf-07104091 monotherapy dose escalation topline data readout](https://sec-api.dev/pdufa/pf-07104091-monotherapy) | PFE | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer | scheduled | "NCT04553133 (PF-07104091 as a Single Agent and in Combination Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04553133)) |
| Dec 2026 to Mar 2027 | [Disitamab vedotin topline data readout](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Urothelial Carcinoma | scheduled | "NCT04879329 (A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04879329)) |
| Dec 2026 to Mar 2027 | [Talzenna (talazoparib tosylate) topline data readout](https://sec-api.dev/pdufa/talazoparib) | PFE | Advanced Malignancies; NSCLC; Ovarian Cancer | scheduled | "NCT05059522 (Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05059522)) |
| Dec 2026 to Mar 2027 | [IBRANCE® (palbociclib) topline data readout](https://sec-api.dev/pdufa/palbociclib) | PFE | Breast Cancer | scheduled | "NCT05909397 (Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05909397)) |
| Dec 2026 to Mar 2027 | [Ritlecitinib higher dose topline data readout](https://sec-api.dev/pdufa/ritlecitinib-higher-dose) | PFE | Severe Alopecia Areata | scheduled | "NCT07029711 (A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029711)) |
| Dec 2026 to Mar 2027 | [Litfulo (ritlecitinib tosylate) topline data readout](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Chronic Spontaneous Urticaria | scheduled | "NCT07219615 (A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219615)) |
| Dec 2026 to Mar 2027 | [Litfulo (ritlecitinib tosylate) topline data readout](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Hidradenitis Suppurativa | scheduled | "NCT07228390 (A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07228390)) |
| Dec 2026 to Mar 2027 | [VLA15 topline data readout](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | scheduled | "NCT07500506 (A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07500506)) |
| December 2026 | [Ritlecitinib higher dose primary completion](https://sec-api.dev/pdufa/ritlecitinib-higher-dose) | PFE | Severe Alopecia Areata | scheduled | "NCT07029711 (A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029711)) |
| December 2026 | [VLA15 primary completion](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | scheduled | "NCT07500506 (A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07500506)) |
| December 2026 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Hidradenitis Suppurativa | scheduled | "NCT07228390 (A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07228390)) |
| December 2026 | [Disitamab vedotin primary completion](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Urothelial Carcinoma | scheduled | "NCT04879329 (A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04879329)) |
| December 2026 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Chronic Spontaneous Urticaria | scheduled | "NCT07219615 (A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219615)) |
| December 2026 | [IBRANCE® (palbociclib) primary completion](https://sec-api.dev/pdufa/palbociclib) | PFE | Breast Cancer | scheduled | "NCT05909397 (Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05909397)) |
| December 2026 | [Pf-07104091 monotherapy dose escalation primary completion](https://sec-api.dev/pdufa/pf-07104091-monotherapy) | PFE | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer | scheduled | "NCT04553133 (PF-07104091 as a Single Agent and in Combination Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04553133)) |
| December 2026 | [Talzenna (talazoparib tosylate) primary completion](https://sec-api.dev/pdufa/talazoparib) | PFE | Advanced Malignancies; NSCLC; Ovarian Cancer | scheduled | "NCT05059522 (Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05059522)) |
| Jan to Apr 2027 | [Rsvpref topline data readout](https://sec-api.dev/pdufa/rsvpref) | PFE | Lower Respiratory Tract Illness | scheduled | "NCT05035212 (Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-18 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05035212)) |
| Jan to Apr 2027 | [Disitamab vedotin topline data readout](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Urothelial Carcinoma | scheduled | "NCT05911295 (Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05911295)) |
| Jan to Apr 2027 | [Rsvpref topline data readout](https://sec-api.dev/pdufa/rsvpref) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07653100 (A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07653100)) |
| January 2027 | [Rsvpref primary completion](https://sec-api.dev/pdufa/rsvpref) | PFE | Lower Respiratory Tract Illness | scheduled | "NCT05035212 (Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-18 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05035212)) |
| January 2027 | [Rsvpref primary completion](https://sec-api.dev/pdufa/rsvpref) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07653100 (A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07653100)) |
| January 2027 | [Disitamab vedotin primary completion](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Urothelial Carcinoma | scheduled | "NCT05911295 (Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05911295)) |
| Feb to May 2027 | [Mevrometostat topline data readout](https://sec-api.dev/pdufa/mevrometostat) | PFE | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06551324 (A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-28 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06551324)) |
| February 2027 | [Mevrometostat primary completion](https://sec-api.dev/pdufa/mevrometostat) | PFE | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06551324 (A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-28 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06551324)) |
| Mar to Jun 2027 | [Xeljanz (tofacitinib citrate) topline data readout](https://sec-api.dev/pdufa/tofacitinib) | PFE | Ulcerative Colitis | scheduled | "NCT04624230 (Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-17 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04624230)) |
| Mar to Jun 2027 | [Atm-avi topline data readout](https://sec-api.dev/pdufa/atm-avi) | PFE | Gram-negative Bacterial Infections | scheduled | "NCT05639647 (Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05639647)) |
| Mar to Jun 2027 | [Litfulo (ritlecitinib tosylate) topline data readout](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Vitiligo | scheduled | "NCT06163326 (A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06163326)) |
| Mar to Jun 2027 | [Pg4 topline data readout](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT06524414 (A Study to Learn About How a New Pneumococcal Vaccine Works in Infants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06524414)) |
| Mar to Jun 2027 | [Pf-07275315 dose 1 topline data readout](https://sec-api.dev/pdufa/pf-07275315) | PFE | Asthma | scheduled | "NCT06977581 (A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06977581)) |
| March 2027 | [Pg4 primary completion](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT06524414 (A Study to Learn About How a New Pneumococcal Vaccine Works in Infants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06524414)) |
| March 2027 | [Pf-07275315 dose 1 primary completion](https://sec-api.dev/pdufa/pf-07275315) | PFE | Asthma | scheduled | "NCT06977581 (A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06977581)) |
| March 2027 | [Xeljanz (tofacitinib citrate) primary completion](https://sec-api.dev/pdufa/tofacitinib) | PFE | Ulcerative Colitis | scheduled | "NCT04624230 (Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-17 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04624230)) |
| March 2027 | [Atm-avi primary completion](https://sec-api.dev/pdufa/atm-avi) | PFE | Gram-negative Bacterial Infections | scheduled | "NCT05639647 (Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05639647)) |
| March 2027 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Vitiligo | scheduled | "NCT06163326 (A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06163326)) |
| Apr to Jul 2027 | [Part a: atm-avi single dose, cohorts 1-4 topline data readout](https://sec-api.dev/pdufa/part-a-atm-avi-single-dose-cohorts-1-4) | PFE | Gram-negative Bacterial Infection | scheduled | "NCT06462235 (A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06462235)) |
| Apr to Jul 2027 | [Pg4 multivalent vaccine topline data readout](https://sec-api.dev/pdufa/pg4-multivalent-vaccine) | PFE | Pneumococcal Disease | scheduled | "NCT07794748 (A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794748)) |
| April 2027 | [Part a: atm-avi single dose, cohorts 1-4 primary completion](https://sec-api.dev/pdufa/part-a-atm-avi-single-dose-cohorts-1-4) | PFE | Gram-negative Bacterial Infection | scheduled | "NCT06462235 (A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06462235)) |
| April 2027 | [Pg4 multivalent vaccine primary completion](https://sec-api.dev/pdufa/pg4-multivalent-vaccine) | PFE | Pneumococcal Disease | scheduled | "NCT07794748 (A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794748)) |
| May to Aug 2027 | [Cibinqo (abrocitinib) topline data readout](https://sec-api.dev/pdufa/abrocitinib) | PFE | Eczema | scheduled | "NCT06807268 (A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06807268)) |
| May to Aug 2027 | [Rsvpref topline data readout](https://sec-api.dev/pdufa/rsvpref) | PFE | Adult; Healthy Participants | scheduled | "NCT07819097 (A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-16 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07819097)) |
| May 2027 | [Cibinqo (abrocitinib) primary completion](https://sec-api.dev/pdufa/abrocitinib) | PFE | Eczema | scheduled | "NCT06807268 (A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06807268)) |
| May 2027 | [Rsvpref primary completion](https://sec-api.dev/pdufa/rsvpref) | PFE | Adult; Healthy Participants | scheduled | "NCT07819097 (A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-16 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07819097)) |
| Jun to Sep 2027 | [Vaccine candidate #1 topline data readout](https://sec-api.dev/pdufa/vaccine-candidate-1) | PFE | Healthy Adults | scheduled | "NCT07431853 (A Study to Learn About mRNA Vaccines Against Influenza in Adults): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-22 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07431853)) |
| June 2027 | [Vaccine candidate #1 primary completion](https://sec-api.dev/pdufa/vaccine-candidate-1) | PFE | Healthy Adults | scheduled | "NCT07431853 (A Study to Learn About mRNA Vaccines Against Influenza in Adults): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-22 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07431853)) |
| Jul to Oct 2027 | [Litfulo (ritlecitinib tosylate) topline data readout](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo | scheduled | "NCT06072183 (A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06072183)) |
| Jul to Oct 2027 | [PF-07248144 topline data readout](https://sec-api.dev/pdufa/pf-07248144) | PFE | Breast Cancer | scheduled | "NCT07062965 (A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07062965)) |
| July 2027 | [PF-07248144 primary completion](https://sec-api.dev/pdufa/pf-07248144) | PFE | Breast Cancer | scheduled | "NCT07062965 (A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07062965)) |
| July 2027 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo | scheduled | "NCT06072183 (A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06072183)) |
| Aug to Nov 2027 | [Elrexfio (elranatamab) topline data readout](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | scheduled | "NCT05317416 (Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05317416)) |
| Aug to Nov 2027 | [PF-08653945 topline data readout](https://sec-api.dev/pdufa/pf-08653945) | PFE | Overweight; Obesity; Overweight and/or Obesity | scheduled | "NCT07575932 (A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07575932)) |
| August 2027 | [Elrexfio (elranatamab) primary completion](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | scheduled | "NCT05317416 (Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05317416)) |
| August 2027 | [PF-08653945 primary completion](https://sec-api.dev/pdufa/pf-08653945) | PFE | Overweight; Obesity; Overweight and/or Obesity | scheduled | "NCT07575932 (A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07575932)) |
| Sep to Dec 2027 | [Mevrometostat topline data readout](https://sec-api.dev/pdufa/mevrometostat) | PFE | Metastatic Castration-Resistant Prostate Cancer | scheduled | "NCT06629779 (A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06629779)) |
| Sep to Dec 2027 | [Ibuzatrelvir topline data readout](https://sec-api.dev/pdufa/ibuzatrelvir) | PFE | COVID-19 Infection | scheduled | "NCT07013474 (A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07013474)) |
| Sep to Dec 2027 | [Met097 injection topline data readout](https://sec-api.dev/pdufa/met097) | PFE | Obesity and Overweight | scheduled | "NCT07311850 (Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-21 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07311850)) |
| September 2027 | [Met097 injection primary completion](https://sec-api.dev/pdufa/met097) | PFE | Obesity and Overweight | scheduled | "NCT07311850 (Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-21 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07311850)) |
| September 2027 | [Ibuzatrelvir primary completion](https://sec-api.dev/pdufa/ibuzatrelvir) | PFE | COVID-19 Infection | scheduled | "NCT07013474 (A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07013474)) |
| September 2027 | [Mevrometostat primary completion](https://sec-api.dev/pdufa/mevrometostat) | PFE | Metastatic Castration-Resistant Prostate Cancer | scheduled | "NCT06629779 (A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06629779)) |
| October 2027 | [Ibuzatrelvir primary completion](https://sec-api.dev/pdufa/ibuzatrelvir) | PFE | COVID-19 SARS-CoV-2 Infection | scheduled | "NCT06679140 (A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06679140)) |
| Oct 2027 to Jan 2028 | [Ibuzatrelvir topline data readout](https://sec-api.dev/pdufa/ibuzatrelvir) | PFE | COVID-19 SARS-CoV-2 Infection | scheduled | "NCT06679140 (A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06679140)) |
| Oct 2027 to Jan 2028 | [PF-08653944 topline data readout](https://sec-api.dev/pdufa/pf-08653944) | PFE | Obesity; Overweight and/or Obesity; Overweight | scheduled | "NCT07400653 (A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-12 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07400653)) |
| October 2027 | [PF-08653944 primary completion](https://sec-api.dev/pdufa/pf-08653944) | PFE | Obesity; Overweight and/or Obesity; Overweight | scheduled | "NCT07400653 (A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-12 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07400653)) |
| Dec 2027 to Mar 2028 | [Tukysa (tucatinib) topline data readout](https://sec-api.dev/pdufa/tucatinib) | PFE | Colorectal Neoplasms | scheduled | "NCT05253651 (A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05253651)) |
| Dec 2027 to Mar 2028 | [Pg4 topline data readout](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT07660198 (Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07660198)) |
| December 2027 | [Pg4 primary completion](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT07660198 (Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07660198)) |
| December 2027 | [Tukysa (tucatinib) primary completion](https://sec-api.dev/pdufa/tucatinib) | PFE | Colorectal Neoplasms | scheduled | "NCT05253651 (A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05253651)) |
| Jan to Apr 2028 | [Ponsegromab topline data readout](https://sec-api.dev/pdufa/ponsegromab) | PFE | Cachexia; Metastatic Pancreatic Ductal Adenocarcinoma | scheduled | "NCT06989437 (A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-01-23 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06989437)) |
| Jan to Apr 2028 | [VLA15 topline data readout](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Borreliosis | scheduled | "NCT07226882 (A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-27 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226882)) |
| January 2028 | [Ponsegromab primary completion](https://sec-api.dev/pdufa/ponsegromab) | PFE | Cachexia; Metastatic Pancreatic Ductal Adenocarcinoma | scheduled | "NCT06989437 (A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-01-23 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06989437)) |
| January 2028 | [VLA15 primary completion](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Borreliosis | scheduled | "NCT07226882 (A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-27 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226882)) |
| Feb to May 2028 | [Rsvpref topline data readout](https://sec-api.dev/pdufa/rsvpref) | PFE | RSV Infection | scheduled | "NCT06866405 (A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-24 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06866405)) |
| Feb to May 2028 | [PF-08049820 topline data readout](https://sec-api.dev/pdufa/pf-08049820) | PFE | Atopic Dermatitis; Eczema, Atopic | scheduled | "NCT07216027 (A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07216027)) |
| Feb to May 2028 | [Rsvpref vaccine topline data readout](https://sec-api.dev/pdufa/rsvpref-vaccine) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07768345 (A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07768345)) |
| Feb to May 2028 | [Berobenatide topline data readout](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity; Overweight and/or Obesity; Overweight | scheduled | "NCT07845500 (A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-16 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07845500)) |
| February 2028 | [PF-08049820 primary completion](https://sec-api.dev/pdufa/pf-08049820) | PFE | Atopic Dermatitis; Eczema, Atopic | scheduled | "NCT07216027 (A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07216027)) |
| February 2028 | [Rsvpref vaccine primary completion](https://sec-api.dev/pdufa/rsvpref-vaccine) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07768345 (A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07768345)) |
| February 2028 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity; Overweight and/or Obesity; Overweight | scheduled | "NCT07845500 (A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-16 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07845500)) |
| February 2028 | [Rsvpref primary completion](https://sec-api.dev/pdufa/rsvpref) | PFE | RSV Infection | scheduled | "NCT06866405 (A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-24 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06866405)) |
| Mar to Jun 2028 | [Litfulo (ritlecitinib tosylate) topline data readout](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Alopecia Areata | scheduled | "NCT06873945 (A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-19 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06873945)) |
| Mar to Jun 2028 | [PF-08046054 topline data readout](https://sec-api.dev/pdufa/pf-08046054) | PFE |  | scheduled | "NCT07144280 (A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07144280)) |
| Mar to Jun 2028 | [PF-08634404 topline data readout](https://sec-api.dev/pdufa/pf-08634404) | PFE |  | scheduled | "NCT07476287 (Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07476287)) |
| Mar to Jun 2028 | [Tilrekimig topline data readout](https://sec-api.dev/pdufa/tilrekimig) | PFE | Atopic Dermatitis | scheduled | "NCT07765888 (A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07765888)) |
| Mar to Jun 2028 | [Berobenatide topline data readout](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity; Overweight | scheduled | "NCT07792954 (A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-14 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07792954)) |
| March 2028 | [PF-08046054 primary completion](https://sec-api.dev/pdufa/pf-08046054) | PFE |  | scheduled | "NCT07144280 (A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07144280)) |
| March 2028 | [Tilrekimig primary completion](https://sec-api.dev/pdufa/tilrekimig) | PFE | Atopic Dermatitis | scheduled | "NCT07765888 (A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07765888)) |
| March 2028 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity; Overweight | scheduled | "NCT07792954 (A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-14 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07792954)) |
| March 2028 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Alopecia Areata | scheduled | "NCT06873945 (A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-19 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06873945)) |
| March 2028 | [PF-08634404 primary completion](https://sec-api.dev/pdufa/pf-08634404) | PFE |  | scheduled | "NCT07476287 (Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07476287)) |
| Apr to Jul 2028 | [Litfulo (ritlecitinib tosylate) topline data readout](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Alopecia Areata | scheduled | "NCT07733765 (A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07733765)) |
| Apr to Jul 2028 | [Berobenatide topline data readout](https://sec-api.dev/pdufa/berobenatide) | PFE | Apnea; Sleep Disorders; Overweight and/or Obesity | scheduled | "NCT07823608 (A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07823608)) |
| April 2028 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Alopecia Areata | scheduled | "NCT07733765 (A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07733765)) |
| April 2028 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Apnea; Sleep Disorders; Overweight and/or Obesity | scheduled | "NCT07823608 (A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07823608)) |
| May to Aug 2028 | [Low dose pf-07328948 topline data readout](https://sec-api.dev/pdufa/low-dose-pf-07328948) | PFE | Heart Failure | scheduled | "NCT06991257 (A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06991257)) |
| May to Aug 2028 | [PF-08653944 topline data readout](https://sec-api.dev/pdufa/pf-08653944) | PFE | Obesity; Overweight and/or Obesity; Overweight | scheduled | "NCT07595549 (A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07595549)) |
| May 2028 | [PF-08653944 primary completion](https://sec-api.dev/pdufa/pf-08653944) | PFE | Obesity; Overweight and/or Obesity; Overweight | scheduled | "NCT07595549 (A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07595549)) |
| May 2028 | [Low dose pf-07328948 primary completion](https://sec-api.dev/pdufa/low-dose-pf-07328948) | PFE | Heart Failure | scheduled | "NCT06991257 (A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06991257)) |
| Jun to Sep 2028 | [Berobenatide topline data readout](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity; Overweight | scheduled | "NCT07874633 (A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07874633)) |
| June 2028 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Apnea; Sleep Disorders; Overweight and/or Obesity | scheduled | "NCT07881757 (A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-01 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07881757)) |
| Jun to Sep 2028 | [Berobenatide topline data readout](https://sec-api.dev/pdufa/berobenatide) | PFE | Apnea; Sleep Disorders; Overweight and/or Obesity | scheduled | "NCT07881757 (A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-01 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07881757)) |
| June 2028 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity; Overweight | scheduled | "NCT07874633 (A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07874633)) |
| Jul to Oct 2028 | [PF-08634404 topline data readout](https://sec-api.dev/pdufa/pf-08634404) | PFE | Carcinoma; Non-Small-Cell Lung; Lung Cancer (NSCLC) | scheduled | "NCT07489066 (Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-29 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07489066)) |
| July 2028 | [PF-08634404 primary completion](https://sec-api.dev/pdufa/pf-08634404) | PFE | Carcinoma; Non-Small-Cell Lung; Lung Cancer (NSCLC) | scheduled | "NCT07489066 (Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-29 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07489066)) |
| Aug to Nov 2028 | [Berobenatide topline data readout](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity; Overweight and/or Obesity; Knee Osteoarthritis | scheduled | "NCT07915609 (A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-21 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07915609)) |
| Aug to Nov 2028 | [Berobenatide topline data readout](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity; Overweight; Osteoarthritis of the Knee | scheduled | "NCT07919678 (A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-22 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07919678)) |
| August 2028 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity; Overweight and/or Obesity; Knee Osteoarthritis | scheduled | "NCT07915609 (A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-21 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07915609)) |
| August 2028 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity; Overweight; Osteoarthritis of the Knee | scheduled | "NCT07919678 (A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-22 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07919678)) |
| Sep to Dec 2028 | [Marstacimab topline data readout](https://sec-api.dev/pdufa/marstacimab) | PFE | Hemophilia A; Hemophilia B | scheduled | "NCT05611801 (A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05611801)) |
| Sep to Dec 2028 | [Sigvotatug vedotin topline data readout](https://sec-api.dev/pdufa/sigvotatug-vedotin) | PFE |  | scheduled | "NCT06758401 (This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-05 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06758401)) |
| Sep to Dec 2028 | [Mevrometostat topline data readout](https://sec-api.dev/pdufa/mevrometostat) | PFE |  | scheduled | "NCT07028853 (This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-12 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07028853)) |
| Sep to Dec 2028 | [Tilrekimig topline data readout](https://sec-api.dev/pdufa/tilrekimig) | PFE | Atopic Dermatitis | scheduled | "NCT07783425 (A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07783425)) |
| September 2028 | [Sigvotatug vedotin primary completion](https://sec-api.dev/pdufa/sigvotatug-vedotin) | PFE |  | scheduled | "NCT06758401 (This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-05 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06758401)) |
| September 2028 | [Tilrekimig primary completion](https://sec-api.dev/pdufa/tilrekimig) | PFE | Atopic Dermatitis | scheduled | "NCT07783425 (A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07783425)) |
| September 2028 | [Marstacimab primary completion](https://sec-api.dev/pdufa/marstacimab) | PFE | Hemophilia A; Hemophilia B | scheduled | "NCT05611801 (A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05611801)) |
| September 2028 | [Mevrometostat primary completion](https://sec-api.dev/pdufa/mevrometostat) | PFE |  | scheduled | "NCT07028853 (This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-12 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07028853)) |
| Oct 2028 to Jan 2029 | [Nurtec Odt (rimegepant sulfate) topline data readout](https://sec-api.dev/pdufa/rimegepant) | PFE | Preventive Treatment of Migraine | scheduled | "NCT07729462 (A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-21 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07729462)) |
| Oct 2028 to Jan 2029 | [Berobenatide topline data readout](https://sec-api.dev/pdufa/berobenatide) | PFE | Urinary Incontinence, Stress; Overweight and/or Obesity | scheduled | "NCT07932925 (The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07932925)) |
| October 2028 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Urinary Incontinence, Stress; Overweight and/or Obesity | scheduled | "NCT07932925 (The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07932925)) |
| October 2028 | [Nurtec Odt (rimegepant sulfate) primary completion](https://sec-api.dev/pdufa/rimegepant) | PFE | Preventive Treatment of Migraine | scheduled | "NCT07729462 (A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-21 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07729462)) |
| Nov 2028 to Feb 2029 | [Multivalent group b streptococcus vaccine topline data readout](https://sec-api.dev/pdufa/multivalent-group-b-streptococcus-vaccine) | PFE | Healthy | scheduled | "NCT07160244 (BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-06 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07160244)) |
| Nov 2028 to Feb 2029 | [20vpnc topline data readout](https://sec-api.dev/pdufa/20vpnc) | PFE | Pneumococcal Diseases | scheduled | "NCT07754539 (A Study to Evaluate 20vPnC in Healthy Chinese Infants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07754539)) |
| November 2028 | [Multivalent group b streptococcus vaccine primary completion](https://sec-api.dev/pdufa/multivalent-group-b-streptococcus-vaccine) | PFE | Healthy | scheduled | "NCT07160244 (BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-06 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07160244)) |
| November 2028 | [20vpnc primary completion](https://sec-api.dev/pdufa/20vpnc) | PFE | Pneumococcal Diseases | scheduled | "NCT07754539 (A Study to Evaluate 20vPnC in Healthy Chinese Infants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07754539)) |
| Dec 2028 to Mar 2029 | [C.difficile vaccine topline data readout](https://sec-api.dev/pdufa/c-difficile-vaccine) | PFE | Clostridoides Difficile Associated Disease | scheduled | "NCT07282665 (A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-11 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07282665)) |
| Dec 2028 to Mar 2029 | [Pg4 topline data readout](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT07573462 (A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07573462)) |
| December 2028 | [C.difficile vaccine primary completion](https://sec-api.dev/pdufa/c-difficile-vaccine) | PFE | Clostridoides Difficile Associated Disease | scheduled | "NCT07282665 (A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-11 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07282665)) |
| December 2028 | [Pg4 primary completion](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT07573462 (A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07573462)) |
| Jan to Apr 2029 | [Rimegepant/bhv3000 topline data readout](https://sec-api.dev/pdufa/rimegepant-bhv3000) | PFE | Pediatric Migraine | scheduled | "NCT04649242 (Randomized Study in Children and Adolescents With Migraine: Acute Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-09 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04649242)) |
| Jan to Apr 2029 | [IBRANCE® (palbociclib) topline data readout](https://sec-api.dev/pdufa/palbociclib) | PFE | Breast Cancer | scheduled | "NCT06760637 (Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06760637)) |
| January 2029 | [IBRANCE® (palbociclib) primary completion](https://sec-api.dev/pdufa/palbociclib) | PFE | Breast Cancer | scheduled | "NCT06760637 (Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06760637)) |
| January 2029 | [Rimegepant/bhv3000 primary completion](https://sec-api.dev/pdufa/rimegepant-bhv3000) | PFE | Pediatric Migraine | scheduled | "NCT04649242 (Randomized Study in Children and Adolescents With Migraine: Acute Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-09 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04649242)) |
| Feb to May 2029 | [PF-08634404 topline data readout](https://sec-api.dev/pdufa/pf-08634404) | PFE |  | scheduled | "NCT07222566 (Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-27 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222566)) |
| Feb to May 2029 | [Berobenatide topline data readout](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity | scheduled | "NCT07794774 (A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-21 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794774)) |
| Feb to May 2029 | [Rsvpref (regimen a) topline data readout](https://sec-api.dev/pdufa/rsvpref-regimen-a) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07885956 (A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-02-07 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07885956)) |
| February 2029 | [Rsvpref (regimen a) primary completion](https://sec-api.dev/pdufa/rsvpref-regimen-a) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07885956 (A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-02-07 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07885956)) |
| February 2029 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity | scheduled | "NCT07794774 (A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-21 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794774)) |
| February 2029 | [PF-08634404 primary completion](https://sec-api.dev/pdufa/pf-08634404) | PFE |  | scheduled | "NCT07222566 (Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-27 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222566)) |
| Mar to Jun 2029 | [Nurtec Odt (rimegepant sulfate) topline data readout](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | scheduled | "NCT05156398 (Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-27 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05156398)) |
| Mar to Jun 2029 | [Berobenatide topline data readout](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity | scheduled | "NCT07794761 (A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-14 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794761)) |
| March 2029 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity | scheduled | "NCT07794761 (A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-14 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794761)) |
| March 2029 | [Nurtec Odt (rimegepant sulfate) primary completion](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | scheduled | "NCT05156398 (Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-27 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05156398)) |
| Apr to Jul 2029 | [Cibinqo (abrocitinib) topline data readout](https://sec-api.dev/pdufa/abrocitinib) | PFE | Atopic Dermatitis | scheduled | "NCT07823595 (Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-04-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07823595)) |
| April 2029 | [Cibinqo (abrocitinib) primary completion](https://sec-api.dev/pdufa/abrocitinib) | PFE | Atopic Dermatitis | scheduled | "NCT07823595 (Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-04-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07823595)) |
| Jun to Sep 2029 | [Etrasimod topline data readout](https://sec-api.dev/pdufa/etrasimod) | PFE | Ulcerative Colitis | scheduled | "NCT03950232 (An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06-19 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03950232)) |
| Jun to Sep 2029 | [Etrasimod topline data readout](https://sec-api.dev/pdufa/etrasimod) | PFE | Ulcerative Colitis | scheduled | "NCT05287126 (A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-06-16 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05287126)) |
| June 2029 | [PF-08634404 primary completion](https://sec-api.dev/pdufa/pf-08634404) | PFE | Endometrial Neoplasms; Endometrial Cancer | scheduled | "NCT07578649 (Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-01 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07578649)) |
| Jun to Sep 2029 | [PF-08634404 topline data readout](https://sec-api.dev/pdufa/pf-08634404) | PFE | Endometrial Neoplasms; Endometrial Cancer | scheduled | "NCT07578649 (Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-01 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07578649)) |
| Jun to Sep 2029 | [Pg4 topline data readout](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT07629440 (A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-05 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07629440)) |
| June 2029 | [Tilrekimig primary completion](https://sec-api.dev/pdufa/tilrekimig) | PFE | Asthma | scheduled | "NCT07772921 (A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-01 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07772921)) |
| Jun to Sep 2029 | [Tilrekimig topline data readout](https://sec-api.dev/pdufa/tilrekimig) | PFE | Asthma | scheduled | "NCT07772921 (A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-01 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07772921)) |
| Jun to Sep 2029 | [Tilrekimig topline data readout](https://sec-api.dev/pdufa/tilrekimig) | PFE | Asthma | scheduled | "NCT07869043 (A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-07 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07869043)) |
| June 2029 | [Pg4 primary completion](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT07629440 (A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-05 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07629440)) |
| June 2029 | [Tilrekimig primary completion](https://sec-api.dev/pdufa/tilrekimig) | PFE | Asthma | scheduled | "NCT07869043 (A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-07 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07869043)) |
| June 2029 | [Etrasimod primary completion](https://sec-api.dev/pdufa/etrasimod) | PFE | Ulcerative Colitis | scheduled | "NCT05287126 (A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-06-16 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05287126)) |
| June 2029 | [Etrasimod primary completion](https://sec-api.dev/pdufa/etrasimod) | PFE | Ulcerative Colitis | scheduled | "NCT03950232 (An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06-19 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03950232)) |
| Jul to Oct 2029 | [Tukysa (tucatinib) topline data readout](https://sec-api.dev/pdufa/tucatinib) | PFE | Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; HER2 Low Breast Neoplasms | scheduled | "NCT06157892 (A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-07-28 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06157892)) |
| Jul to Oct 2029 | [Marstacimab topline data readout](https://sec-api.dev/pdufa/marstacimab) | PFE | Hemophilia A or B | scheduled | "NCT07923981 (A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without Inhibitors): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07923981)) |
| July 2029 | [Marstacimab primary completion](https://sec-api.dev/pdufa/marstacimab) | PFE | Hemophilia A or B | scheduled | "NCT07923981 (A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without Inhibitors): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07923981)) |
| July 2029 | [Tukysa (tucatinib) primary completion](https://sec-api.dev/pdufa/tucatinib) | PFE | Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; HER2 Low Breast Neoplasms | scheduled | "NCT06157892 (A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-07-28 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06157892)) |
| Aug to Nov 2029 | [IBRANCE® (palbociclib) topline data readout](https://sec-api.dev/pdufa/palbociclib) | PFE |  | scheduled | "NCT04606446 (Study of PF-07248144 in Advanced or Metastatic Solid Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-27 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04606446)) |
| August 2029 | [IBRANCE® (palbociclib) primary completion](https://sec-api.dev/pdufa/palbociclib) | PFE |  | scheduled | "NCT04606446 (Study of PF-07248144 in Advanced or Metastatic Solid Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-27 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04606446)) |
| Oct 2029 to Jan 2030 | [PF-07220060 topline data readout](https://sec-api.dev/pdufa/pf-07220060) | PFE | Liposarcoma; Prostate Cancer; Advanced Breast Cancer | scheduled | "NCT04557449 (Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-07 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04557449)) |
| October 2029 | [PF-07220060 primary completion](https://sec-api.dev/pdufa/pf-07220060) | PFE | Liposarcoma; Prostate Cancer; Advanced Breast Cancer | scheduled | "NCT04557449 (Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-07 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04557449)) |
| Dec 2029 to Mar 2030 | [IBRANCE® (palbociclib) topline data readout](https://sec-api.dev/pdufa/palbociclib) | PFE | Breast Cancer; Head and Neck Cancer | scheduled | "NCT05226871 (Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-12-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05226871)) |
| December 2029 | [IBRANCE® (palbociclib) primary completion](https://sec-api.dev/pdufa/palbociclib) | PFE | Breast Cancer; Head and Neck Cancer | scheduled | "NCT05226871 (Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-12-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05226871)) |
| Feb to May 2030 | [Nurtec Odt (rimegepant sulfate) topline data readout](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | scheduled | "NCT06616194 (A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-02-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06616194)) |
| Feb to May 2030 | [PF-08634404 topline data readout](https://sec-api.dev/pdufa/pf-08634404) | PFE | Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms | scheduled | "NCT07222800 (Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02-23 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222800)) |
| February 2030 | [PF-08634404 primary completion](https://sec-api.dev/pdufa/pf-08634404) | PFE | Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms | scheduled | "NCT07222800 (Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02-23 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222800)) |
| February 2030 | [Nurtec Odt (rimegepant sulfate) primary completion](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | scheduled | "NCT06616194 (A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-02-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06616194)) |
| Jun to Sep 2030 | [Ritlecitinib higher dose topline data readout](https://sec-api.dev/pdufa/ritlecitinib-higher-dose) | PFE | Severe Alopecia Areata | scheduled | "NCT07029828 (A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029828)) |
| Jun to Sep 2030 | [PF-08634404 topline data readout](https://sec-api.dev/pdufa/pf-08634404) | PFE | Small Cell Lung Cancer (SCLC) | scheduled | "NCT07226999 (Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-06-14 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226999)) |
| June 2030 | [PF-08634404 primary completion](https://sec-api.dev/pdufa/pf-08634404) | PFE | Small Cell Lung Cancer (SCLC) | scheduled | "NCT07226999 (Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-06-14 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226999)) |
| June 2030 | [Ritlecitinib higher dose primary completion](https://sec-api.dev/pdufa/ritlecitinib-higher-dose) | PFE | Severe Alopecia Areata | scheduled | "NCT07029828 (A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029828)) |
| Jul to Oct 2030 | [Rimegepant (pf-07899801) topline data readout](https://sec-api.dev/pdufa/rimegepant-pf-07899801) | PFE | Acute Treatment of Migraine | scheduled | "NCT04743141 (Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04743141)) |
| Jul to Oct 2030 | [Marstacimab topline data readout](https://sec-api.dev/pdufa/marstacimab) | PFE | Hemophilia A; Hemophilia B | scheduled | "NCT05145127 (Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05145127)) |
| Jul to Oct 2030 | [PF-06823859 topline data readout](https://sec-api.dev/pdufa/pf-06823859) | PFE | Myositis | scheduled | "NCT05895786 (A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-29 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05895786)) |
| July 2030 | [PF-06823859 primary completion](https://sec-api.dev/pdufa/pf-06823859) | PFE | Myositis | scheduled | "NCT05895786 (A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-29 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05895786)) |
| July 2030 | [Rimegepant (pf-07899801) primary completion](https://sec-api.dev/pdufa/rimegepant-pf-07899801) | PFE | Acute Treatment of Migraine | scheduled | "NCT04743141 (Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04743141)) |
| July 2030 | [Marstacimab primary completion](https://sec-api.dev/pdufa/marstacimab) | PFE | Hemophilia A; Hemophilia B | scheduled | "NCT05145127 (Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05145127)) |
| Sep to Dec 2030 | [Etrasimod topline data readout](https://sec-api.dev/pdufa/etrasimod) | PFE | Colitis, Ulcerative | scheduled | "NCT07470879 (A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-09-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07470879)) |
| September 2030 | [Etrasimod primary completion](https://sec-api.dev/pdufa/etrasimod) | PFE | Colitis, Ulcerative | scheduled | "NCT07470879 (A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-09-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07470879)) |
| Oct 2030 to Jan 2031 | [Elrexfio (elranatamab) topline data readout](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | scheduled | "NCT05623020 (A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10-18 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05623020)) |
| Oct 2030 to Jan 2031 | [Pf-07275315 dose 1 topline data readout](https://sec-api.dev/pdufa/pf-07275315) | PFE | Moderate to Severe Chronic Obstructive Pulmonary Disease | scheduled | "NCT07363694 (A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-10-24 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07363694)) |
| October 2030 | [Elrexfio (elranatamab) primary completion](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | scheduled | "NCT05623020 (A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10-18 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05623020)) |
| October 2030 | [Pf-07275315 dose 1 primary completion](https://sec-api.dev/pdufa/pf-07275315) | PFE | Moderate to Severe Chronic Obstructive Pulmonary Disease | scheduled | "NCT07363694 (A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-10-24 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07363694)) |

## Drugs

- [20-valent pneumococcal conjugate vaccine](https://sec-api.dev/pdufa/20-valent-pneumococcal-conjugate-vaccine): Pneumococcal Disease
- [20vpnc](https://sec-api.dev/pdufa/20vpnc): Pneumococcal Diseases
- [Cibinqo (abrocitinib)](https://sec-api.dev/pdufa/abrocitinib): To treat refractory, moderate-to-severe atopic dermatitis, Dermatitis, Atopic, Eczema, Atopic Dermatitis
- [Abrilada (adalimumab-afzb)](https://sec-api.dev/pdufa/adalimumab-afzb): 
- [Atm-avi](https://sec-api.dev/pdufa/atm-avi): Gram-negative Bacterial Infections
- [Inlyta (axitinib)](https://sec-api.dev/pdufa/axitinib): 
- [BENDEKA (bendamustine)](https://sec-api.dev/pdufa/bendamustine): 
- [Berobenatide](https://sec-api.dev/pdufa/berobenatide): Obesity, Urinary Incontinence, Stress, Apnea
- [Zirabev (bevacizumab-bvzr)](https://sec-api.dev/pdufa/bevacizumab-bvzr): 
- [Bosulif (bosutinib monohydrate)](https://sec-api.dev/pdufa/bosutinib): 
- [Brentuximab vedotin](https://sec-api.dev/pdufa/brentuximab-vedotin): Diffuse Large B-cell Lymphoma, Melanoma
- [C.difficile vaccine](https://sec-api.dev/pdufa/c-difficile-vaccine): Clostridoides Difficile Associated Disease
- [Xalkori (crizotinib)](https://sec-api.dev/pdufa/crizotinib): 
- [Vizimpro (dacomitinib)](https://sec-api.dev/pdufa/dacomitinib): 
- [Fragmin (dalteparin sodium)](https://sec-api.dev/pdufa/dalteparin): 
- [Daptomycin (daptomycin)](https://sec-api.dev/pdufa/daptomycin): 
- [IGALMI® (dexmedetomidine)](https://sec-api.dev/pdufa/dexmedetomidine): opioid withdrawal symptoms in adults with opioid use disorder undergoing a methadone taper, opioid withdrawal symptoms in adults with opioid use disorder, Agitation,Psychomotor
- [Disitamab vedotin](https://sec-api.dev/pdufa/disitamab-vedotin): Urothelial Carcinoma, Carcinoma, Non-Small-Cell Lung
- [Doxercalciferol (doxercalciferol)](https://sec-api.dev/pdufa/doxercalciferol): 
- [Elrexfio (elranatamab)](https://sec-api.dev/pdufa/elranatamab): Multiple Myeloma
- [Encorafenib](https://sec-api.dev/pdufa/encorafenib): Metastatic Colorectal Cancer, Melanoma
- [Retacrit (epoetin alfa-epbx)](https://sec-api.dev/pdufa/epoetin-alfa-epbx): 
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod): Ulcerative Colitis, Colitis, Ulcerative
- [Velsipity (etrasimod arginine)](https://sec-api.dev/pdufa/etrasimod-arginine): To treat moderately to severely active ulcerative colitis in adults
- [Toviaz (fesoterodine fumarate)](https://sec-api.dev/pdufa/fesoterodine): 
- [Nivestym (filgrastim-aafi)](https://sec-api.dev/pdufa/filgrastim-aafi): 
- [Fordadistrogene movaparvovec](https://sec-api.dev/pdufa/fordadistrogene-movaparvovec): Muscular Dystrophy, Duchenne, Duchenne Muscular Dystrophy
- [Mylotarg (gemtuzumab ozogamicin)](https://sec-api.dev/pdufa/gemtuzumab-ozogamicin): 
- [Daurismo (glasdegib maleate)](https://sec-api.dev/pdufa/glasdegib): 
- [Ibuzatrelvir](https://sec-api.dev/pdufa/ibuzatrelvir): COVID-19 Infection, COVID-19 SARS-CoV-2 Infection
- [Inclacumab](https://sec-api.dev/pdufa/inclacumab): Sickle Cell Disease
- [Ixifi (infliximab-qbtx)](https://sec-api.dev/pdufa/infliximab-qbtx): 
- [Besponsa (inotuzumab ozogamicin)](https://sec-api.dev/pdufa/inotuzumab-ozogamicin): 
- [Lorbrena (lorlatinib)](https://sec-api.dev/pdufa/lorlatinib): 
- [Low dose pf-07328948](https://sec-api.dev/pdufa/low-dose-pf-07328948): Heart Failure
- [Mannitol 25% (mannitol)](https://sec-api.dev/pdufa/mannitol): 
- [Marstacimab](https://sec-api.dev/pdufa/marstacimab): Hemophilia A or B, Hemophilia A
- [Hympavzi (marstacimab-hncq)](https://sec-api.dev/pdufa/marstacimab-hncq): To prevent or reduce bleeding episodes related to hemophilia A or BPress Release
- [Depo-Provera (medroxyprogesterone acetate)](https://sec-api.dev/pdufa/medroxyprogesterone): 
- [Met097 injection](https://sec-api.dev/pdufa/met097): Obesity, Obesity and Overweight, Obesity in Diabetes
- [Methotrexate Preservative Free (methotrexate)](https://sec-api.dev/pdufa/methotrexate): primary vitreoretinal lymphoma
- [Mevrometostat](https://sec-api.dev/pdufa/mevrometostat): Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer
- [Morphine Sulfate (morphine sulfate)](https://sec-api.dev/pdufa/morphine): 
- [Multivalent group b streptococcus vaccine](https://sec-api.dev/pdufa/multivalent-group-b-streptococcus-vaccine): Healthy
- [Troxyca Er (naltrexone hydrochloride; oxycodone hydrochloride)](https://sec-api.dev/pdufa/naltrexone-oxycodone): 
- [Nda219112](https://sec-api.dev/pdufa/nda219112): 
- [Nirmatrelvir](https://sec-api.dev/pdufa/nirmatrelvir): COVID-19
- [PAXLOVID® (nirmatrelvir-ritonavir)](https://sec-api.dev/pdufa/nirmatrelvir-ritonavir): 
- [IBRANCE® (palbociclib)](https://sec-api.dev/pdufa/palbociclib): Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Breast Cancer
- [Protonix Iv (pantoprazole sodium)](https://sec-api.dev/pdufa/pantoprazole): 
- [Part a: atm-avi single dose, cohorts 1-4](https://sec-api.dev/pdufa/part-a-atm-avi-single-dose-cohorts-1-4): Gram-negative Bacterial Infection
- [Nyvepria (pegfilgrastim-apgf)](https://sec-api.dev/pdufa/pegfilgrastim-apgf): 
- [Pemetrexed Ditromethamine (pemetrexed ditromethamine)](https://sec-api.dev/pdufa/pemetrexed-ditromethamine): 
- [PF-06823859](https://sec-api.dev/pdufa/pf-06823859): Myositis, Lupus Erythematosus, Systemic
- [PF-06835375](https://sec-api.dev/pdufa/pf-06835375): Primary Immune Thrombocytopenia
- [Pf-06838435 (formerly spk-9001)](https://sec-api.dev/pdufa/pf-06838435-formerly-spk-9001): Hemophilia B
- [Pf-07104091 monotherapy dose escalation](https://sec-api.dev/pdufa/pf-07104091-monotherapy): Small Cell Lung Cancer
- [PF-07220060](https://sec-api.dev/pdufa/pf-07220060): Breast Cancer, Liposarcoma
- [Pf-07220060 cdk4 inhibitor](https://sec-api.dev/pdufa/pf-07220060-cdk4-inhibitor): Advanced or Metastatic Breast Cancer
- [PF-07248144](https://sec-api.dev/pdufa/pf-07248144): Breast Cancer
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315): Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease, Atopic Dermatitis
- [PF-07868489](https://sec-api.dev/pdufa/pf-07868489): Pulmonary Hypertension
- [PF-07976016](https://sec-api.dev/pdufa/pf-07976016): Obesity
- [PF-08046054](https://sec-api.dev/pdufa/pf-08046054): Non-small Cell Carcinoma
- [PF-08049820](https://sec-api.dev/pdufa/pf-08049820): Atopic Dermatitis
- [PF-08634404](https://sec-api.dev/pdufa/pf-08634404): Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Intestinal Neoplasms, Carcinoma, Endometrial Neoplasms, Small Cell Lung Cancer (SCLC)
- [PF-08653944](https://sec-api.dev/pdufa/pf-08653944): Obesity
- [PF-08653945](https://sec-api.dev/pdufa/pf-08653945): Overweight
- [Pg4](https://sec-api.dev/pdufa/pg4): Pneumococcal Disease
- [Pg4 multivalent vaccine](https://sec-api.dev/pdufa/pg4-multivalent-vaccine): Pneumococcal Disease
- [Zosyn (piperacillin sodium; tazobactam sodium)](https://sec-api.dev/pdufa/piperacillin-tazobactam): 
- [Ponsegromab](https://sec-api.dev/pdufa/ponsegromab): Cachexia
- [Respiratory syncytial virus prefusion f subunit vaccine](https://sec-api.dev/pdufa/respiratory-syncytial-virus-prefusion-f-subunit-vaccine): Respiratory Syncytial Virus (RSV)
- [Nurtec Odt (rimegepant sulfate)](https://sec-api.dev/pdufa/rimegepant): Migraine, Menstrual Migraine, Preventive Treatment of Migraine
- [Rimegepant/bhv3000](https://sec-api.dev/pdufa/rimegepant-bhv3000): Pediatric Migraine
- [Rimegepant (pf-07899801)](https://sec-api.dev/pdufa/rimegepant-pf-07899801): Acute Treatment of Migraine
- [Litfulo (ritlecitinib tosylate)](https://sec-api.dev/pdufa/ritlecitinib): To treat severely patchy hair loss, Stable Nonsegmental Vitiligo, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Chronic Spontaneous Urticaria
- [Ritlecitinib higher dose](https://sec-api.dev/pdufa/ritlecitinib-higher-dose): Severe Alopecia Areata
- [Ruxience (rituximab-pvvr)](https://sec-api.dev/pdufa/rituximab-pvvr): 
- [Rsvpref](https://sec-api.dev/pdufa/rsvpref): RSV Infection, Adult, Lower Respiratory Tract Illness, Respiratory Syncytial Virus (RSV)
- [Rsvpref (regimen a)](https://sec-api.dev/pdufa/rsvpref-regimen-a): Respiratory Syncytial Virus (RSV)
- [Rsvpref vaccine](https://sec-api.dev/pdufa/rsvpref-vaccine): Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus
- [Sigvotatug vedotin](https://sec-api.dev/pdufa/sigvotatug-vedotin): Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
- [Ngenla (somatrogon-ghla)](https://sec-api.dev/pdufa/somatrogon-ghla): To treat growth failure due to inadequate secretion of endogenous growth hormone
- [Talzenna (talazoparib tosylate)](https://sec-api.dev/pdufa/talazoparib): Advanced Malignancies
- [Talazoparib plus enzalutamide](https://sec-api.dev/pdufa/talazoparib-plus-enzalutamide): Prostate Cancer
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig): Asthma, Atopic Dermatitis
- [Tisotumab vedotin](https://sec-api.dev/pdufa/tisotumab-vedotin): Colorectal Neoplasms
- [Tivdak (tisotumab vedotin-tftv)](https://sec-api.dev/pdufa/tisotumab-vedotin-tftv): 
- [Xeljanz (tofacitinib citrate)](https://sec-api.dev/pdufa/tofacitinib): Ulcerative Colitis
- [Trazimera (trastuzumab-qyyp)](https://sec-api.dev/pdufa/trastuzumab-qyyp): 
- [Tukysa (tucatinib)](https://sec-api.dev/pdufa/tucatinib): Breast Neoplasms, Colorectal Neoplasms, HER2 Positive Breast Cancer
- [Vaccine candidate #1](https://sec-api.dev/pdufa/vaccine-candidate-1): Healthy Adults
- [VLA15](https://sec-api.dev/pdufa/vla15): Lyme Disease, Lyme Borreliosis
- [Zavzpret ® (zavegepant)](https://sec-api.dev/pdufa/zavegepant): To treat migraineDrug Trails Snapshot, Migraine

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/pfe/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PFE catalysts: PFIZER INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/pfe/catalysts

```bibtex
@misc{secapidev_companies_pfe_catalysts_20261116,
  title        = {PFE catalysts: PFIZER INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/pfe/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_pfe_catalysts_20261116","title":"PFE catalysts: PFIZER INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/pfe/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
